Barcode designs a proprietary technology for use for personalized cancer drug screening.
Barcode designs a proprietary technology designed for use for personalized cancer drug screening. Its proprietary technology quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor within the patient's own body, enabling physicians to access a new tool that matches each patient with the optimally potent medicine, during the different stages of the disease to improve cancer care.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 9, 2019 | Series A | $4M | 1 | — | — | Detail |